Research Article

Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis

Shuaifei Ji1,*, Babo Zhang1,*, Xianda Wang1, Heng Shi1, Lixin Yu1 and Xiaocheng Wang2

1 School of basic medicine, Air Force Military Medical University, Xi’an, Shanxi, China; 2 Center of Clinical Aerospace Medicine, School of Aerospace Medicine, Key Laboratory of Aerospace Medicine of Ministry of Education, Air Force Medical University, Xi’an, China

Correspondence: Xiaocheng Wang (wxcnose@126.com)

Many studies have demonstrated the effects of statin therapy on platelet, but it is controversial that whether statin could reduce mean platelet volume (MPV) in patients with the risk of cardiovascular diseases. To further improve the clinical significance of MPV in those patients and explore new function of statin, we conducted this research. Relevant studies were selected by searching electronic databases (PubMed, Embase and Cochrane Library) and reference lists of related articles by hand. Two reviewers independently assessed eligibility and quality of the studies. Eventually, we included ten studies, a total of 1189 patients with the risk of cardiovascular diseases. Consolidating relevant data and comparing the changes of MPV before and after statin treatment, we found that statin could decrease MPV [standard mean difference (SMD) = −0.47 (−0.71–0.23)], which was statistically significant (P=0.0001). Subgroup analysis suggested that when ≥55 years, this decrease did not occur [SMD = −0.06 (−0.18, 0.06)]. Drug type, sample size, ethnicity, mean age and quality of included article were sources of heterogeneity. Therefore, statin therapy could reduce MPV significantly and exhibited antiplatelet activity, which is of great importance in clarifying the clinical significance of MPV in cardiovascular events and the prevention of cardiovascular events.

Introduction

Mean platelet volume (MPV), reflecting the size of the platelets, is a potentially useful marker of platelet activity. Increased MPV level has been identified as an independent risk factor for cardiovascular diseases and vascular risk factors such as coronary heart disease [1], diabetes [2], smoking [3], hypertension [4], dyslipidemia [5] obesity [6] and atrial fibrillation [7].

Statin inhibits 3-hydroxy-3-methylglutaryl co-enzyme A reductase in the mevalonate pathway, simultaneously promotes the low density lipoprotein metabolism and the high density lipoprotein synthesis, which play an essential role in reducing the risk of cardiovascular events. In recent years, many studies have reported possible effects of statin on MPV, but the conclusions have not been uniform and are highly controversial. Some studies have linked statin to lower MPV [8–15], others have found no link [16,17]. So do statin affect MPV? Could MPV be an independent risk factor for patients taking statin with cardiovascular risk factors? Based on this controversial topic and these questions, we conducted a systematic review and meta-analysis to study the relationship between statin therapy and MPV, with a view to providing a reference for clinical practice.

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Materials and methods

Literature search

This systematic review and meta-analysis are reported in accordance with the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) Statement. Literature was retrieved by formal search of electronic databases (PubMed, Embase and Cochrane Library) without date limitation. To achieve the maximum sensitivity of the search strategy, we used appropriated free text and thesaurus terms including “Hydroxymethylglutaryl CoA Reductase Inhibitors”, “statin”, “mean platelet volume”. We also searched reference lists of related articles by hand to obtain more studies. All studies were limited to English language and the retrieval strategy of Pubmed as follow: (((((Mean Platelet Volumes[Title/Abstract] OR Platelet Volume, Mean[Title/Abstract] OR Platelet Volumes, Mean[Title/Abstract] OR Platelet Volume, Mean[Title/Abstract] OR Mean Platelet Volume[Title/Abstract] OR Mean Platelet Volume[Title/Abstract] OR Mean Platelet Volume[Title/Abstract] OR Mean Platelet Volume[Title/Abstract] OR Mean Platelet Volume[Title/Abstract])) OR “Mean Platelet Volume”[Mesh])) AND (((((Hydroxymethylglutaryl CoA Reductase Inhibitors[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA Reductase[Title/Abstract] OR Reductase Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, HMG-CoA Reductase[Title/Abstract] OR Inhibitors, HMG CoA Reductase[Title/Abstract] OR Reductase Inhibitors, HMG-CoA[Title/Abstract] OR HMG-CoA Reductase Inhibitors[Title/Abstract] OR HMG-CoA Reductase Inhibitors[Title/Abstract] OR Statins, HMG-CoA[Title/Abstract] OR HMG-CoA Statins[Title/Abstract] OR HMG-CoA Statins[Title/Abstract] OR Inhibitors, HMG-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA Statins[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract] OR Inhibitors, Hydroxymethylglutaryl-CoA[Title/Abstract])) OR (*statin[Title/Abstract] OR atorvastatin[Title/Abstract] OR rosuvastatin[Title/Abstract] OR pravastatin[Title/Abstract] OR statins[Title/Abstract])) OR "Hydroxymethylglutaryl-CoA Reductase Inhibitors”[Mesh]).

Inclusion and exclusion criteria

Inclusion criteria: (1) Patients with the risk of cardiovascular diseases, such as diabetes mellitus, dyslipidemia and hypertension; (2) The data must contain standard mean difference (SMD). If only median and interquartile range (IQR) provided, standard difference (SD) will be calculated according to the Cochrane manual equation: SD = IQR/1.359 [18]; (3) The article must provide baseline data. (4) Abstracts providing necessary data will be included in order to avoid bias.

Exclusion criteria: (1) Reviews, case reports, letters and unpublished studies; (2) Animal-based experiments; (3) In vitro studies; (4) Unrelated studies; (5) Not cardiovascular diseases.

Data abstraction and quality assessment

Two authors (S.F.J. and B.B.Z.) independently extracted the original data. Disagreement was resolved by discussion. If the two authors could not reach a consensus, the result was reviewed by the third author (X.D.W.). The extracted data were consisted of the follow items: the first author’s name, publication year, population (Ethnicity), methods, matching criteria, total number of cases and age (years).

The quality assessment of the included trials was undertaken independently by two review authors (H.S. and L.X.Y.), following Newcastle–Ottawa Scale (NOS), which is composed of three parts: selection, comparability and exposure. It is a semi-quantitative scale, and a score of 0–9 stars was assigned to each study. A total score of <7 was considered poor and 7–9 was deemed high quality.

Statistical analysis

We measured the statin effect on continuous outcomes (e.g. change of mean platelet volume) by SMD with 95% confidence interval (CI). We used Review manager 5.3 and Stata14.0 software to perform the meta-analysis in the present study. Sensitivity analysis was performed by changing effect model and remerging data after excluding abstracts. Begg’s test and egger’s test were used to detect the asymmetry of the funnel plot, which (P<0.05) were considered to be representative of statistically significant publication bias. Heterogeneity among studies was assessed by I² statistic. I² > 50% indicated evidence of heterogeneity. If heterogeneity existed among the studies, the random effects model was used to estimate the pooled effect size. Otherwise, the fixed effects model was adopted. Subgroup analyses regarding drug type, follow-up, sample size, ethnicity, mean age and NOS score, were also performed to explore source of heterogeneity.
Results

Literature search
After initial retrieval, 167 articles were obtained. 15 articles were removed after repeated examination. 152 articles were excluded after reading the title and abstract, which included four case reports, six animal researches, ten reviews and letters, and 122 unrelated studies such as relationship between statin and cancers, researches about platelet function. The remaining ten articles included eight case control studies [8,10–12,14–17] and two abstracts [9,13]. Two of these studies [10,11] reported the effects of two statins on MPV, so we considered a total of 12 studies to be included in the data analysis. The flowchart of literature inclusion was shown in Figure 1.

Characteristics of the selected studies
The characteristics included in the article are shown in Table 1. Among included studies [8–17], there were seven papers published in the past 5 years [9–11,14–17], eight papers about Caucasian [8,10,12–17], two papers about Asian [9,11], five papers with high-quality [8,10,14,15,17], two abstracts without NOS score [9,13]. Statins included atorvastatin (initial dose level to maximum dose level, 10–80 mg/d), rosuvastatin (initial dose level to excess maximum dose level, 10–40 mg/d), pravastatin (initial dose level to maximum dose level, 20–40 mg/d) and simvastatin (initial dose level, 5–20 mg/d). The number of patients ranged from 10 to 261, and there were four literatures with the number of patients greater than or equal to 100. The follow-up time span was 4–24 weeks, and the follow-up time of six articles was more than or equal to 12 weeks [8,9,13,15–17]. Risks of cardiovascular diseases mainly include: diabetes mellitus and dyslipidemia. In terms of data types, IQR of mean platelet volume was provided in two studies [16,17].

Meta-analysis of statin therapy and MPV
The pooled analysis is shown in Figure 2. The results showed that the mean platelet volume significantly down-regulated after statin treatment \(\text{SMD} = -0.47 (-0.71\text{--0.23})\), which was statistically significant \(P=0.0001\). There was significant heterogeneity among studies \((P<0.0001, I^2 = 87\%)\), so the random-effect model was used.

Subgroup analysis
Subgroup analysis based on drug type, follow-up, sample size, ethnicity, mean age and NOS score, was performed and the results are shown in Table 2. In terms of specific drug administration, the mean platelet volume could be
Table 1 Main characteristics of eligible studies

| Study and year | Country | NOS | Drug          | Follow-up (Weeks) | Disease                    | Patients | Dosage       |
|----------------|---------|-----|---------------|-------------------|----------------------------|----------|--------------|
| Akin F 2013    | Turkey  | 7   | Atorvastatin  | 24                | Hypercholesterolemia       | 79       | 10–80 mg/d  |
| Akuyz A 2015   | Turkey  | 7   | Rosuvastatin  | 4–12              | Diabetes mellitus          | 178      | 40 mg/d      |
| Broijersen A 1994 | Sweden | 6   | Pravastatin   | 4                 | Hypercholesterolemia       | 10       | 20–40 mg/d  |
| Coban E 2007   | Turkey  | 7   | Rosuvastatin  | 12                | Dyslipidemia               | 30       | 10 mg/d      |
| Gungoren F 2015 | Turkey | 7   | Rosuvastatin  | 24                | Hypercholesterolemia       | 261      | 10–40 mg/d  |
| Kucera M 2015  | Slovak  | 6   | Atorvastatin  | 12                | Hypercholesterolemia, diabetes mellitus | 74 | 10–80 mg/d  |
| Sivri N 2013   | Turkey  | 7   | Rosuvastatin  | 4–8               | Hypercholesterolemia       | 71       | 10–40 mg/d  |
| Sivri N 2013   | Turkey  | 7   | Rosuvastatin  | 4–8               | Hypercholesterolemia, diabetes mellitus | 71 | 10–40 mg/d  |
| Akin F 2013    | Turkey  | 7   | Atorvastatin  | 4–12              | Diabetes mellitus          | 178      | 40 mg/d      |
| Sivri N 2013   | Turkey  | 7   | Atorvastatin  | 4–12              | Hypercholesterolemia       | 71       | 10–40 mg/d  |
| Sivri N 2013   | Turkey  | 7   | Atorvastatin  | 4–12              | Hypercholesterolemia, diabetes mellitus | 71 | 10–40 mg/d  |
| Butt, N F 2018 | Pakistan No | &lt;50 | Atorvastatin | 12                | Dyslipidemia               | 100      | 20 mg/d      |

Abbreviation: NOS, Newcastle–Ottawa Scale.

Figure 2. Effect of statin therapy on mean platelet volume

Table 2 Subgroup analysis about effect of statin therapy on mean platelet volume

| Subgroup               | Standard mean difference (95% CI) | Heterogeneity | P-value |
|------------------------|-----------------------------------|---------------|---------|
| Drug type              |                                   |               |         |
| Atorvastatin           | −0.52 (−0.94, −0.10)              | 87            | &lt;0.00001 |
| Rosuvastatin           | −0.22 (−0.40, −0.03)              | 9              | = 0.33  |
| Follow-up              |                                   |               |         |
| ≥12 week               | −0.34 (−0.69, −0.02)              | 90            | &lt;0.00001 |
| &lt;12 week            | −0.61 (−0.95, −0.26)              | 84            | &lt;0.00001 |
| Sample size            |                                   |               |         |
| ≥100                   | −0.43 (−0.85, −0.01)              | 94            | &lt;0.00001 |
| &lt;100                | −0.49 (−0.78, −0.20)              | 77            | &lt;0.0001 |
| Ethnicity              |                                   |               |         |
| Asian                  | −1.04 (−1.22, −0.85)              | 0             | 0.663    |
| Caucasian              | −0.26 (−0.44, −0.08)              | 68.4          | = 0.001  |
| Mean age               |                                   |               |         |
| ≥55 years              | −0.06 (−0.18, 0.06)               | 0             | 0.675    |
| &lt;55 years           | −0.66 (−0.94, −0.38)              | 64.5          | = 0.015  |
| NOS score              |                                   |               |         |
| ≥7                     | −0.21 (−0.37, −0.05)              | 48.5          | 0.084    |
| &lt;7                  | −0.67 (−1.23, −0.11)              | 84.5          | 0.000    |
Funnel plot about effect of statin therapy on mean platelet volume

lowered by the atorvastatin \([\text{SMD} = −0.52 (−0.94, −0.10)]\) and rosuvastatin \([\text{SMD} = −0.22 (−0.40, −0.03)]\), and the results were statistically significant. The heterogeneity of the rosuvastatin group significantly increased \((I^2 = 9\%)\). Likewise, results of ethnicity \([\text{Asian, SMD} = −1.04 (−1.22, −0.85); \text{Caucasian, SMD} = −0.26 (−0.44, −0.08)]\) and NOS score group \([≥7, \text{SMD} = −0.21 (−0.37, −0.05); <7, \text{SMD} = −0.67 (−1.23, −0.11)]\) were similar to drug type, mean platelet volume showing a statistically significant down-regulation, and the heterogeneity of Asian group \((I^2 = 0\%)\) and \(≥7\) group \((I^2 = 48.5\%)\) also significantly increased. Although analysis results of follow-up \([≥12\ weeks, \text{SMD} = −0.34 (−0.69, −0.02); <12\ weeks, \text{SMD} = −0.61 (−0.95, −0.26)]\) and sample size group \([≥100, \text{SMD} = −0.43 (−0.85, −0.01); <100, \text{SMD} = −0.49 (−0.78, −0.20)]\) exhibited obvious difference, heterogeneity failed to decrease significantly, which suggested both of follow-up and sample size were not the source of heterogeneity. The age range was divided by 55 years \((≥55\ years\ and\ <55\ years)\), and heterogeneity of the two group showed a significant down-regulation \((I^2 = 0\%, 64.5\%)\). In <55 years group, statin therapy could decrease mean platelet volume \([\text{SMD} = −0.66 (−0.94, −0.38)]\) which was statistically significant, but this similar result did not appear in ≥55 years group \([\text{SMD} = −0.06 (−0.18, 0.06)]\).

Sensitivity analysis
Sensitivity analysis was achieved by transforming effect model and re-synthesizing data with excluding abstracts. The combined result was statistically significance and with no significant change \([\text{SMD} = −0.39 (−0.47, −0.31), P<0.05]\) after the random model was converted to a fixed model. The result of re-synthesizing data with excluding abstracts was similar \([\text{SMD} = −0.39 (−0.64, −0.14), P<0.05]\). Sensitivity analysis showed that our meta-analysis results were stable and reliable.

Assessment of publication bias and linear correlation of MPV changes by intensity statin
A funnel plot (Figure 3), Begg’s test and Egger’s test were performed to investigate the potential publication bias. The results showed no significant publication bias existed \((\text{Begg’s } P=0.451>0.05, \text{Egger’s } P=0.271>0.05)\). Linear correlation of MPV changes by intensity statin is shown in Figure 4, and the result suggested that there was a positive correlation.
Figure 4. Linear correlation of MPV changes by intensity statin

Discussion

Our study shows that statin do reduce mean platelet volume in patients with cardiovascular disease risk factors, which indirectly suggests that statin could inhibit platelet function. To our knowledge, this is the first study to demonstrate the effect of statin on platelets through systematic review and meta-analysis, providing a powerful supplement for the diversity of clinical effects of statin.

In clinical practice, cardiovascular disease is a kind of common and multiple diseases, with a long course and rapid progress. Platelets play an important role in the development of cardiovascular diseases, especially atherosclerosis. Cardiovascular disease is mainly caused by thrombosis. In the vascular lumen, platelet aggregation and adhesion lead to thrombosis, which causes narrowing and obstruction of the lumen, myocardial ischemia, hypoxia and eventually necrosis. Obesity, diabetes hypertension and dyslipidemia are risk factors for cardiovascular diseases. Many studies have shown that platelets are highly reactive in these risk factors, which in turn can accelerate the development of cardiovascular diseases [19–22]. Platelet activation is often accompanied by an increase in volume, i.e., increased MPV. Coban et al. [23] observed a mean MPV significantly higher in the group of obese women, in comparison with the non-obese group (8.18 ± 1.09 vs 8.01 ± 0.95 fL, \( P = 0.004 \)). In addition, Coban et al. [24] in another case–control study with 200 subjects and Ozkan et al. [25] in a case–control study with 108 children aged 6–16 years reached similar conclusions.

Patients with Type 2 DM have a higher risk of coagulation abnormalities and thromboembolic events [26,27], and elevated MPV and its significance as marker in Type 2 DM have been elaborated in many studies [28–31]. The same is true for those with Arterial hypertension or dyslipidemia [32,33]. Therefore, MPV is an important marker for patients with cardiovascular disease risk factors and represents abnormal platelet function. Improving platelet function and reducing MPV are important in preventing cardiovascular events.

Statin can significantly reduce blood cholesterol levels and the risk of cardiovascular disease and ischemic stroke [34,35]. In addition to inhibiting lipid synthesis, statin also has antioxidant [36], anti-inflammatory [37] and anti-thrombotic effects [38]. Our study showed that statin can reduce MPV and regulate platelet function, which may be mainly through multiple mechanisms to combat platelet activation. CD36 (glycoprotein IV) is expressed in a variety of cells on the surface of the single glycoprotein, and ox-LDL binds to platelet membrane CD36 to generate endogenous ROS, which can promote platelet activation and thrombosis [39]. Simvastatin and pravastatin can inhibit platelet activation by directly interacting with CD36 or by affecting CD36 intracellular signal transduction pathways [38]. Peroxisome proliferator-activated receptor (PPAR) is a member of the nuclear steroid hormone receptor superfamily, and its biological functions of transcriptional regulation are mainly performed by binding specific DNA reaction elements and retinol X heterodimer receptors [40]. Simvastatin is dose-dependent on the induction of PPAR\( \alpha \) and PPAR\( \gamma \) activation, and the up-regulation of PPAR\( \gamma \) expression also inhibited collagen-induced plaque aggregation. Meanwhile, elevated expression of CD62, bispecific phosphatase 2 and Ca2 + mobilization induced by simvastatin could further increase antiplatelet activity [41]. Lee et al. [42] reported effect of cyclicAMP-eNOS/NO-cyclicAMP pathway
in antiplatelet activity induced by statin. Activation of cyclicAMP-eNOS/NO-cyclicAMP pathway could cause phospholipase Cy2-Protein kinase C-mitogen activated protein kinase-TXA2 cascade reactions inhibition, which suggests antiplatelet activity. Ni et al. [43] reported atorvastatin can increase the level of guanosine cyclophosphate in platelets and delay the maximum activation rate of p-selectin and CD41, which inhibited activation of platelet induced by H-Gly-Tyr-Pro-GlyLys-Phe-OH (GYP) and thrombin. Serebruany et al. [44] demonstrated that multiple statin can reduce the expression of thrombin receptor protein kinase-activated receptor-1, and reduce platelet activation and thrombosis in the evaluation of the primary prevention effect of statin therapy in patients with metabolic syndrome. Therefore, it is not hard to understand why statin could reduce MPV.

In the ten studies, we included the results of Gungoren et al. [17] and Kucera et al. [16] indicated that statin therapy may not affect MPV. After comprehensive analysis, we found that the biggest difference between these two articles and other articles is the original data type of MPV, both of two using median and IQR. For this reason, we removed these two articles and recomputed the data, and the result [SMD = −0.58 (−0.82, −0.34), P = 0.000] verified our idea to a certain degree.

Our study indicates that statin therapy could reduce MPV regardless of drug type, follow-up time, sample size, ethnicity, and <55 years subgroup, and we also find that drug type, ethnicity, age, and literature quality are sources of heterogeneity. Sensitivity analysis and publication bias test show that our results are stable and reliable. The age group ≥55 years shows no effect [SMD = −0.06 (−0.18, 0.06)], and we fail to explain it.

Of course, we need to point out the limitations of our research. First of all, the time interval of blood sample collection and analysis, and the use of different anticoagulants (such as citrate and EDTA) may be the influencing factors, but due to insufficient data, it cannot be verified by subgroup analysis; Second, the follow-up time of the included studies was relatively long, which could not guarantee that the patients did not have behaviors that interfered with the study results; Then, we could not perform subgroup analysis about pravastatin and simvastatin; Finally, there is no way to know if there is a drug dose effect because the doses overlap and cannot be analyzed further.

Fortunately, our study demonstrated that statin therapy may reduce MPV, indirectly demonstrating platelet inhibition. Given the importance of MPV as a marker of activated platelets and as a predictor of vascular events, this effect of statin therapy is encouraging. What is more, our study suggests when we use MPV to diagnose and monitor patients with cardiovascular disease, we need to pay attention to patients’ statin use.

Funding
This work was supported by Key Researcher and Development Plan in Shaanxi, China [grant number 2018SF-252].

Author Contribution
B.B.Z. and S.F.J. conceived and designed the methods, extracted the original data and drafted the manuscript. B.B.Z., S.F.J. and X.D.W. performed statistical analysis. B.B.Z., L.X.Y. and H.S. interpreted results. X.C.W. revised the manuscript. B.B.Z., S.F.J. and X.C.W. had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of data analysis.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
CI, confidence interval; DM, diabetes mellitus; IQR, interquartile range; MPV, mean platelet volume; NOS, Newcastle–Ottawa Scale; ox-LDL, oxidation-low density lipoprotein; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; SD, standard difference; SMD, standard mean difference.

References
1. Gong, J. and Gu, N. (2017) Analysis on correlation of blood stasis syndrome of coronary heart disease and coagulation function and blood platelet parameters. Biomed. Res. 28, 9825–9829.
2. Hudzik, B., Korzonek-Szlacheta, I., Szkozdziński, J., Liszka, R., Lekston, A., Zubelewicz-Szkodzińska, B. et al. (2018) Association between multimorbidity and mean platelet volume in diabetic patients with acute myocardial infarction. Acta Diabetol. 55, 175–183, https://doi.org/10.1007/s00592-017-1079-6.
3. Cho, S.Y., You, E., Lee, H.J., Lee, W.I., and Park, T.S. (2014) Smoking cessation decreases mean platelet volume in healthy Korean populations. Clin. Lab. 60, 1413–1416, https://doi.org/10.7754/ClinLab.2013.130901.
4. Li, G., Zhang, Y.Y., Zhu, Z.W. and Du, J. (2017) Association between mean platelet volume and hypertension incidence. Hypertens. Res. 40, 779–784.
5. Varol, E., Aksoy, F., Bas, H.A., Ari, H. and Ozyaydin, M. (2014) Mean platelet volume is elevated in patients with low high-density lipoprotein cholesterol. Angiology 65, 733–736, https://doi.org/10.1177/0003319713504024.
6 Erdin, I. and Oghlan, F. (2017) Blood count values and ratios for predicting sleep apnea in obese children. Int. J. Pediatr. Otorhinolaryngol. 98, 85, https://doi.org/10.1016/j.ijporl.2017.04.043

7 Akayz, A., Akkoyun, D.C., Degirmenci, H. and Alp, R. (2015) Atrial fibrillation is associated with increased mean platelet volume and apnea hypopnea index in patients with obstructive sleep apnea. Angiology 66, 525–530, https://doi.org/10.1177/0003319714548567

8 Coban, E. and Afacan, B. (2008) The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with dyslipopidemic diet treatment. Platelets 19, 111–114, https://doi.org/10.1080/09537100701230444

9 Butt, N.F., Rathore, R., Laiti, H., Mehmoord, H., Faisal, H.S. and Iqbal, A. (2018) Effect of atorvastatin on hematological parameters in patients with dyslipidemias. Pak. J. Med. Health Sci. 12, 1087–1090

10 Sirvi, N., Tekin, G., Yalta, K., Aksoy, Y., Senen, K. and Yetkin, E. (2013) Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol. Pol. 71, 1042–1047, https://doi.org/10.5603/KP.2013.0259

11 Xian-Yu, J.B., Feng, J.F., Chen, Y.C. and Yang, Y.W. (2015) Effects of simvastatin and atorvastatin on biochemical and hematologic markers in patients with risk of cardiovascular diseases. Int. J. Clin. Exp. Med. 8, 13983–13989

12 Brojersen, A., Eriksson, M., Larsson, P.T., Beck, O., Berglund, L., Angelin, B. et al. (1994) Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. Eur. J. Clin. Invest. 24, 488–498, https://doi.org/10.1111/j.1365-2362.1994.tb02380.x

13 Erdem, G., Tasci, I., Celebi, G., Ozgur, G., Dogru, T., Sonmez, A. et al. (2009) LDL-cholesterol lowering either through therapeutic lifestyle change intervention or HMG-CoA reductase inhibitor treatment decreases mean platelet volume values in people with elevated LDL-cholesterol. Atheroscler. Suppl. 10, 557–561, https://doi.org/10.1016/j.athscs.2015.02.010

14 Akayz, A., Akkoyun, D.C., Degirmenci, H. and Oran, M. (2016) Rosuvastatin decreases mean platelet volume in patients with diabetes mellitus. Angiology 67, 116–120, https://doi.org/10.1177/0003319715584725

15 Akin, F., Ayca, B., Kose, N., Sahin, I., Akin, M.N., Canbek, T.D. et al. (2013) Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. Angiology 64, 621–625, https://doi.org/10.1177/0003319713479154

16 Kucera, M., Balaz, D., Kruzliak, P., Ciccocioppo, R., Oravec, S., Rodrigo, L. et al. (2015) The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinaemia and comparison with plasma atherogeneity indicators – a pilot study. Clin. Biochem. 48, 557–561, https://doi.org/10.1016/j.clinbiochem.2015.02.010

17 Gungoren, F., Besli, F., Caliskan, S., Polat, U., Basar, C. and Serda, O.A. (2015) Statin therapy may not effect NLR and MPV levels in patients with hypercholesterolemia. Angiology 67, 536–540, https://doi.org/10.1177/0003319715604098

18 Higgins, J. and Green, S. (2008) Cochrane Handbook for Systematic Reviews of Interventions, Wiley-Blackwell, Hoboken U.S.

19 Santilli, F., Vazzana, N., Liani, R., Guagnano, M.T. and Davi, G. (2012) Platelet activation in obesity and metabolic syndrome. Obes. Rev. 13, 27–42, https://doi.org/10.1111/j.1467-7689.2011.00930.x

20 Lee, E.Y., Kim, S.J., Song, Y.J., Choi, S.J. and Song, J. (2013) Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb. Res. 132, 692–695, https://doi.org/10.1016/j.thromres.2013.09.035

21 Ulutas, K.T., Dokuyucu, R., Sefl, F., Yengil, E., Sumbu, A.T., Kologrivova, I.V. et al. (2014) Effect of atorvastatin treatment in patients with type 2 diabetes mellitus and red blood cell distribution width - a pilot study. Int. J. Clin. Exp. Med. 7, 955–961

22 Lip, G.Y. (2000) Target organ damage and the prothrombotic state in hypertension. Hypertension 36, 975–977, https://doi.org/10.1161/01.HYP.36.6.975

23 Coban, E., Ozdogan, M., Yazioglu, G. and Akcit, F. (2005) The mean platelet volume in patients with obesity. Int. J. Clin. Pract. 59, 981–982, https://doi.org/10.1111/j.1742-1241.2005.00000.x

24 Coban, E., Yilmaz, A. and Sari, R. (2007) The effect of weight loss on the mean platelet volume in obese patients. Platelets 18, 212–216, https://doi.org/10.1080/10424130701294578

25 Ozkan, E.A., Khosrroshahi, H.E., Serin, H.I., Ozdemir, Z.T., Kic, M., Ekim, M. et al. (2015) The evaluation of carotid intima–media thickness and mean platelet volume values and correlation with cardiac functions in obese children. Int. J. Clin. Exp. Med. 8, 22557–22563

26 Kim, J.H., Bae, H.Y. and Kim, S.Y. (2014) Response: clinical marker of platelet hyperreactivity in diabetes mellitus (diabetes metab j 2013;37:423-8). Diabet. Metab. J. 38, 160–161, https://doi.org/10.4093/dmj.2014.38.2.160

27 Suslova, T.E., Stitozevski, A.V., Ogorkova, O.N., Kravchenko, E.S., Kologrivova, I.V., Amfogenova, Y. et al. (2014) Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP-and N0-dependent mechanisms in the insulin-mediated platelet aggregation. Front. Physiol. 5, 501

28 Han, J.Y., Choi, D.H., Choi, S.W., Kim, B.B., K, Y.J., Chung, J.W. et al. (2013) Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets 24, 401–406, https://doi.org/10.3109/09537104.2012.710858

29 Ulutas, K.T., Dokuyucu, R., Sefl, F., Yengil, E., Sumbu, A.T., Rizaoglu, H. et al. (2014) Evaluation of mean platelet volume in patients with type 2 diabetes mellitus and blood glucose regulation: a marker for atherosclerosis? Int. J. Clin. Exp. Med. 7, 373-423

30 Shimodaira, M., Niwa, T., Nakajima, K., Kobayashi, M., Hanyu, N. and Nakayama, T. (2013) Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normoglycemic individuals. Cardiovasc. Diabetol. 12, 14, https://doi.org/10.1186/1475-2840-12-14

31 Zhou, Z., Chen, H., Sun, M. and Yu, H. (2018) Mean platelet volume and gestational diabetes mellitus: a systematic review and meta-analysis. J. Diabetes Res. 2018, 1985026, https://doi.org/10.1155/2018/1985026

32 Coban, E., Yazioglu, G., Berkant Avci, A. and Akcit, F. (2005) The mean platelet volume in patients with essential and white coat hypertension. Platelets 16, 435–438, https://doi.org/10.1080/10424130500163572

33 Boos, C.J., Beevers, G.D. and Lip, G.Y. (2007) Assessment of platelet activation indices using the ADVIATM 120 amongst ‘high-risk’ patients with hypertension. Ann. Med. 39, 72–78, https://doi.org/10.1080/07853890601040063

34 Amendacca, P. and Tabacchi, J. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 8, 453–463, https://doi.org/10.1016/S1474-4422(09)70058-4

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
35 Mihaylova, B., Emberson, J., Blackwell, L., Keech, A., Simes, J. and Cholesterol Treatment Trialists’ (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet **380**, 581–590, https://doi.org/10.1016/S0140-6736(12)60367-5

36 Margaritis, I., M., Channon, K.M. and Antoniades, C. (2014) Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. *Antioxid. Redox Signal.* **20**, 1198–1215, https://doi.org/10.1089/ars.2013.5430

37 Kawabori, M. and Yenari, M.A. (2015) Inflammatory responses in brain ischemia. *Curr. Med. Chem.* **22**, 1258–1277, https://doi.org/10.2174/0929867322666150209154036

38 Luzak, B., Rywaniak, J., Stanczyk, L. and Watala, C. (2012) Pravastatin and simvastatin improves acetylsalicylic acid-mediated *in vitro* blood platelet inhibition. *Eur. J. Clin. Invest.* **42**, 864–872, https://doi.org/10.1111/j.1365-2362.2012.02661.x

39 Magwenzi, S., Woodward, C., Wraith, K.S., Aburima, A., Raslan, Z., Jones, H. et al. (2015) Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. *Blood* **125**, 2693–2703, https://doi.org/10.1182/blood-2014-05-574491

40 Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K. et al. (2007) Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. *Circ. Res.* **100**, 1442–1451, https://doi.org/10.1161/01.RES.0000268411.49545.9c

41 Du, H., Hu, H., Zheng, H., Hao, J., Yang, J.C. and Cui, W. (2014) Effects of peroxisome proliferator-activated receptor gamma in simvastatin antiplatelet activity: Influences on cAMP and mitogen-activated protein kinases. *Thromb. Res.* **134**, 111–120, https://doi.org/10.1016/j.thromres.2014.05.005

42 Lee, Y.M., Chen, W.F., Chou, D.S., Jayakumar, T., Hou, S.Y., Lee, J.J. et al. (2010) Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. *J. Biomed. Sci.* **17**, 45, https://doi.org/10.1186/1423-0127-17-45

43 Ni, R., Peleg, T. and Gross, P.L. (2012) Atorvastatin delays murine platelet activation *in vivo* even in the absence of endothelial NO synthase. *Arterioscler. Thromb. Vasc. Biol.* **32**, 2609–2615, https://doi.org/10.1161/ATVBAHA.112.300090

44 Serebruany, V.L., Miller, M., Pokrov, A.N., Malinin, A.I., Lowry, D.R., Tanguay, J.F. et al. (2006) Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). *Am. J. Cardiol.* **97**, 1332–1336, https://doi.org/10.1016/j.amjcard.2005.11.058